Among patients with stage T1b, T1c, T2a, or T2b prostate adenocarcinoma and a PSA level of 20 ng per milliliter or less, the use of short-term ADT for 4 months before and during radiotherapy was associated with significantly decreased disease-specific mortality and increased overall survival. According to post hoc risk analysis, the benefit was mainly seen in intermediate-risk, but not low-risk, men. Funded by the National Cancer Institute; RTOG 94-08 ClinicalTrials.gov number, NCT00002597.
This study revealed a reduction in overall survival at 10 years and disease-specific mortality at 10 years. Patients studied were low and moderate risk prostate cancer patients receiving radiotherapy as definitive therapy.
Only the moderate risk patients were shown to have a benefit.